Form 4: Ventyx Biosciences Chief Scientific Officer Executes Stock Transactions

Ventyx Biosciences' Chief Scientific Officer, John Nuss, acquired and sold shares to cover tax obligations related to vesting restricted stock units.

Summary

• John Nuss, the Chief Scientific Officer of Ventyx Biosciences, acquired 34,930 shares of common stock on December 17, 2024, through the vesting of restricted stock units (RSUs).
• These RSUs were granted under the 2021 Equity Incentive Plan and vest over four years, with 25% vesting annually starting December 17, 2022.
• On December 19, 2024, Mr. Nuss sold 13,161 shares at a weighted average price of $2.2553 per share, with prices ranging from $2.205 to $2.38.
• The sale was to cover tax withholding obligations associated with the vesting of the RSUs.
• Following these transactions, Mr. Nuss directly owns 485,701 shares of Ventyx Biosciences common stock.

Sentiment

Score: 7

Explanation: The document reflects routine insider transactions related to equity compensation. There is no indication of positive or negative sentiment, it is a standard process.

Industry Context

This is a routine transaction for a company where equity compensation is a part of the overall compensation package. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• The vesting schedule of 25% annually over four years is a common practice in the biotechnology industry for equity compensation.
• The sale of shares to cover tax obligations is a standard practice among executives who receive equity compensation.
• Many companies in the biotech sector use restricted stock units as a key component of their compensation packages, similar to Ventyx Biosciences.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they are related to routine executive compensation.
• The sale of shares by the Chief Scientific Officer may have a slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Ventyx Biosciences, John Nuss, stock transaction, restricted stock units, insider trading, equity compensation, tax obligations